Key result
Standing SBP ≥140 mm Hg linked to higher cardiovascular and mortality risk, unlike systolic orthostatic increases.
Why the study?
Recent consensus statements combine a blood pressure rise upon standing with standing hypertension, but whether these two components carry similar cardiovascular disease risk associations was unknown.
Are systolic orthostatic increases and elevated standing SBP associated with incident cardiovascular disease and mortality in adults without baseline CVD?
Cohort (n=11,369)
Yes
Are systolic orthostatic increases and elevated standing SBP associated with incident cardiovascular disease and mortality in adults without baseline CVD?
Elevated standing SBP, but not systolic orthostatic increase, is strongly associated with long-term cardiovascular disease outcomes and mortality, challenging current consensus definitions that combine the two.
No takes yet. Share an insight, caveat, or question.
Elevated standing SBP may identify higher-risk adults for monitoring; challenges combined orthostatic definitions but leaves open need for prospective validation.
Dooley et al. (2024) conducted a cohort in Without cardiovascular disease (n=11,369). Standing SBP ≥140 mm Hg and systolic orthostatic increase was evaluated on Incident coronary heart disease, heart failure, stroke, fatal coronary heart disease, and all-cause mortality. Standing SBP ≥140 mm Hg (prevalence 20.1%), but not systolic orthostatic increases (1.8%), was significantly associated with a higher risk of cardiovascular disease outcomes and death over 30 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: